<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053167</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1602</org_study_id>
    <nct_id>NCT03053167</nct_id>
  </id_info>
  <brief_title>Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients</brief_title>
  <official_title>Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients: An Open-label, Single-arm, Multicenter Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irinotecan and raltitrexed are active against advanced colorectal cancer (ACC), act through
      different mechanisms, and have only partially overlapping toxicity profiles. The purpose of
      this study is to evaluate efficacy and safety of irinotecan plus raltitrexed as second-line
      treatment in advanced colorectal cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard initial treatment for patients with advanced colorectal cancer (ACC) not
      amenable for surgical resection is palliative 5-fluorouracil (5-FU)-based chemotherapy.
      However, response rates are low and prognosis remains poor, with median survival times about
      one year. Until recently, second-line therapy options were limited.

      Irinotecan is a semisynthetic camptothecin derivate that acts as a DNA-topoisomerase-1
      inhibitor,its most frequent toxic effects are diarrhea, neutropenia and cholinergic syndrome.
      Raltitrexed is a quinazoline folate-based specific thymidylate synthase inhibitor, its
      clinical activity in this setting is similar to that of modulated 5-FU regimens but with a
      better toxicity profile (mainly asthenia and increased serum transaminase levels). There
      seems to be no cross-resistance between 5-FU and raltitrexed. Irinotecan and raltitrexed have
      different toxicity profiles and modes of action. Both drugs are active as single agents and
      may be given as a short 3-weekly infusion, thus obviating complex schedules or the need for
      implantable venous access devices. Preclinical studies have demonstrated a pronounced
      sequence-dependent synergy between SN-38 (the active metabolite of irinotecan) and
      raltitrexed. It seems then interesting to explore the feasibility and therapeutic potential
      of this association.

      With this background, the investigators have performed this study to evaluate efficacy and
      safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival [PFS]</measure>
    <time_frame>5-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival [OS]</measure>
    <time_frame>12-15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate [ORR]</measure>
    <time_frame>12-15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate [DCR]</measure>
    <time_frame>12-15 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and Degree of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>12-15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Performance Status [WHO-ECOG]</measure>
    <time_frame>12-15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life [WHO-QOL]</measure>
    <time_frame>12-15 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ColoRectal Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan &amp; Raltitrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.
Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1
Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks</description>
    <arm_group_label>Irinotecan &amp; Raltitrexed</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks</description>
    <arm_group_label>Irinotecan &amp; Raltitrexed</arm_group_label>
    <other_name>Sai wei jian</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  life expectancy of at least 3 months;

          -  histological and/or cytological confirmation of ACC;

          -  disease progression while on first-line palliative oxaliplatin &amp; fluoropyrimidine
             chemotherapy or relapse within 6 months after adjuvant oxaliplatin &amp; fluoropyrimidine
             chemotherapy;

          -  wash-out time of 4 weeks after the last chemotherapy infusion or radiotherapy，and
             observed lesions not in the radiotherapy target；

          -  at least one measurable objective tumor lesion by spiral CT examination, the maximum
             diameter ≥ 1cm（according to RECIST 1.1）；

          -  ECOG performance status 0-1；

          -  satisfactory main organ function，laboratory test must meet the following criteria:
             hemoglobin (HGB) ≥90g/L, neutrophil count（ANC） ≥1.5×109/L, platelet count（PLT）
             ≥90×109/L, Serum creatinine（CR）≤1.5 upper normal limitation (UNL)，creatinine clearance
             rate (CCr) ≥60ml/min, total bilirubin (TBil) ≤1.5 upper normal limitation (UNL),
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For
             patients with liver metastasis, the AST/ALT must be ≤5.0 UNL);

          -  For women with child bearing potential, a negative serum or urine pregnancy test
             result should be obtained before enrollment

          -  written informed consent.

        Exclusion Criteria:

          -  prior exposure to irinotecan or raltitrexed;

          -  chronic enteropathy on unresolved bowel obstruction;

          -  Pregnant or lactated women;

          -  previous malignant disease other than carcinoma in situ of the cervix or basal cell
             carcinoma of the skin;

          -  Concurrent administration of any other investigational drug, or have been enrolled in
             other clinical trial with investigational drug treatment within the 30 days of start
             of study treatment；

          -  cerebral metastases or leptomeningeal carcinomatosis;

          -  severe or uncompensated concomitant medical conditions.

          -  Unsuitable for the study or other chemotherapy determined by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YunPeng Liu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YunPeng Liu, PhD</last_name>
    <phone>86-24-83282312</phone>
    <email>cmuliuyunpeng@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zan Teng, PhD</last_name>
    <phone>86-024-83282542</phone>
    <email>tengzan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Liu, MD., PhD</last_name>
      <phone>86-24-83282312</phone>
      <email>cmuliuyunpeng@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yunpeng Liu, MD., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Chiara S, Nobile MT, Tomasello L, Acquati M, Taveggia P, Murolo C, Percivale P, Rosso R. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer. Anticancer Res. 2005 Mar-Apr;25(2B):1391-6.</citation>
    <PMID>15865096</PMID>
  </results_reference>
  <results_reference>
    <citation>Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, de Tejada MR, Rodríguez-García JM, Martínez MP, Martín MS, Sánchez JJ, Barón MG; Oncopaz Cooperative Group and Associated Hospitals. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer. 2004 Apr 19;90(8):1502-7.</citation>
    <PMID>15083176</PMID>
  </results_reference>
  <results_reference>
    <citation>Aparicio J, de las Peñas R, Vicent JM, Garcerá S, Llorca C, Maestu I, Yuste AL, Farrés J. Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Oncology. 2002;63(1):42-7.</citation>
    <PMID>12187070</PMID>
  </results_reference>
  <results_reference>
    <citation>Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol. 2002 Sep;13(9):1424-9.</citation>
    <PMID>12196368</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director of Department of Medical Oncology，The First Hospital of China Medical University</investigator_title>
  </responsible_party>
  <keyword>Raltitrexed</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Second-line Treatment</keyword>
  <keyword>Advanced Colorectal Cancer(ACC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

